Olema Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Olema Pharmaceuticals, Inc. (OLMA)
CIK: 0001750284
Period of Report: 2021-07-20

Reporting Person: Harmon Cyrus (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-19	Common Stock	S	7877	$24.83	Disposed	1091669	Direct
2021-07-20	Common Stock	S	4123	$25.63	Disposed	1087546	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	122028	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

F2: The weighted average sale price for the transaction reported was $24.83, and the range of prices were between $24.75 and $24.95. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: The weighted average sale price for the transaction reported was $25.63, and the range of prices were between $25.14 and $26.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

F4: The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.